Efficacy and safety of rituximab in childhoodonset, difficult-to-treat nephrotic syndrome: A multicenter open-label trial in Korea

Yo Han Ahn, Seong Heon Kim, Kyoung Hee Han, Hyun Jin Choi, Heeyeon Cho, Jung Won Lee, Jae Il Shin, Min Hyun Cho, Joo Hoon Lee, Young Seo Park, Il Soo Ha, Hae Il Cheong, Su Young Kim, Seung Joo Lee, Hee Gyung Kang

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: The anti-CD20 monoclonal antibody rituximab (RTX) has been proposed as a rescue therapy for difficult-to-treat nephrotic syndrome (NS). We conducted a clinical trial to evaluate the efficacy and safety of RTX in children with difficult-to-treat NS dependent on or resistant to steroids and calcineurin inhibitors (CNIs). Methods: A multicenter open-label trial was performed at 8 major pediatric nephrology centers in Korea. The investigation consisted of a randomized controlled trial for steroid- and CNI-dependent NS (DDNS; randomization into the RTX group and the control group, at a ratio of 2:1) and a single-arm study of steroid and CNI-resistant NS (DRNS). DDNS patients in the RTX group and DRNS patients received a single dose of intravenous RTX (375mg/m2 of body surface area) for B-cell depletion. A second RTX dose was administered at week 2 if the first dose failed to achieve depletion of CD19(+) cells. The primary endpoint was rate of maintaining remission at 6 months after treatment for DDNS and rate of remission achievement for DRNS. Results: Sixty-one children with DDNS were enrolled while in remission and randomized to the control group (21 patients) or the RTX group (40 patients). At 6 months after treatment, the remission rates were 74.3% in the RTX group and 31.3% in the control group (P=.003). The mean duration of remission maintenance was significantly higher in the RTX group than in the control group (9.0 vs 2.9 months, P=.004). Of the 23 patients with DRNS enrolled in the single-arm study and treated with RTX, 9 (39.1%) achieved partial or complete remission within 6 months. Depletion of B cells occurred in all patients with RTX therapy. Thirty patients (50.8% of 59 patients analyzed) experienced mild and transient infusion reaction during RTX administration, and most adverse events were mild. Conclusions: RTX administration was safe and effective in patients with difficult-to-treat NS. One or 2 doses of RTX may be sufficient to deplete B cells and achieve better control of pediatric NS.

Original languageEnglish
Article numbere13157
JournalMedicine (United States)
Volume97
Issue number46
DOIs
Publication statusPublished - 2018 Nov 1

Fingerprint

Nephrotic Syndrome
Korea
Safety
Control Groups
B-Lymphocytes
Steroids
Rituximab
Pediatrics
Nephrology
Body Surface Area
Therapeutics
Random Allocation
Randomized Controlled Trials

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Ahn, Yo Han ; Kim, Seong Heon ; Han, Kyoung Hee ; Choi, Hyun Jin ; Cho, Heeyeon ; Lee, Jung Won ; Shin, Jae Il ; Cho, Min Hyun ; Lee, Joo Hoon ; Park, Young Seo ; Ha, Il Soo ; Cheong, Hae Il ; Kim, Su Young ; Lee, Seung Joo ; Kang, Hee Gyung. / Efficacy and safety of rituximab in childhoodonset, difficult-to-treat nephrotic syndrome : A multicenter open-label trial in Korea. In: Medicine (United States). 2018 ; Vol. 97, No. 46.
@article{1fb27b84d9e7420fa06432226b801e87,
title = "Efficacy and safety of rituximab in childhoodonset, difficult-to-treat nephrotic syndrome: A multicenter open-label trial in Korea",
abstract = "Background: The anti-CD20 monoclonal antibody rituximab (RTX) has been proposed as a rescue therapy for difficult-to-treat nephrotic syndrome (NS). We conducted a clinical trial to evaluate the efficacy and safety of RTX in children with difficult-to-treat NS dependent on or resistant to steroids and calcineurin inhibitors (CNIs). Methods: A multicenter open-label trial was performed at 8 major pediatric nephrology centers in Korea. The investigation consisted of a randomized controlled trial for steroid- and CNI-dependent NS (DDNS; randomization into the RTX group and the control group, at a ratio of 2:1) and a single-arm study of steroid and CNI-resistant NS (DRNS). DDNS patients in the RTX group and DRNS patients received a single dose of intravenous RTX (375mg/m2 of body surface area) for B-cell depletion. A second RTX dose was administered at week 2 if the first dose failed to achieve depletion of CD19(+) cells. The primary endpoint was rate of maintaining remission at 6 months after treatment for DDNS and rate of remission achievement for DRNS. Results: Sixty-one children with DDNS were enrolled while in remission and randomized to the control group (21 patients) or the RTX group (40 patients). At 6 months after treatment, the remission rates were 74.3{\%} in the RTX group and 31.3{\%} in the control group (P=.003). The mean duration of remission maintenance was significantly higher in the RTX group than in the control group (9.0 vs 2.9 months, P=.004). Of the 23 patients with DRNS enrolled in the single-arm study and treated with RTX, 9 (39.1{\%}) achieved partial or complete remission within 6 months. Depletion of B cells occurred in all patients with RTX therapy. Thirty patients (50.8{\%} of 59 patients analyzed) experienced mild and transient infusion reaction during RTX administration, and most adverse events were mild. Conclusions: RTX administration was safe and effective in patients with difficult-to-treat NS. One or 2 doses of RTX may be sufficient to deplete B cells and achieve better control of pediatric NS.",
author = "Ahn, {Yo Han} and Kim, {Seong Heon} and Han, {Kyoung Hee} and Choi, {Hyun Jin} and Heeyeon Cho and Lee, {Jung Won} and Shin, {Jae Il} and Cho, {Min Hyun} and Lee, {Joo Hoon} and Park, {Young Seo} and Ha, {Il Soo} and Cheong, {Hae Il} and Kim, {Su Young} and Lee, {Seung Joo} and Kang, {Hee Gyung}",
year = "2018",
month = "11",
day = "1",
doi = "10.1097/MD.0000000000013157",
language = "English",
volume = "97",
journal = "Medicine (United States)",
issn = "0025-7974",
publisher = "Lippincott Williams and Wilkins",
number = "46",

}

Ahn, YH, Kim, SH, Han, KH, Choi, HJ, Cho, H, Lee, JW, Shin, JI, Cho, MH, Lee, JH, Park, YS, Ha, IS, Cheong, HI, Kim, SY, Lee, SJ & Kang, HG 2018, 'Efficacy and safety of rituximab in childhoodonset, difficult-to-treat nephrotic syndrome: A multicenter open-label trial in Korea', Medicine (United States), vol. 97, no. 46, e13157. https://doi.org/10.1097/MD.0000000000013157

Efficacy and safety of rituximab in childhoodonset, difficult-to-treat nephrotic syndrome : A multicenter open-label trial in Korea. / Ahn, Yo Han; Kim, Seong Heon; Han, Kyoung Hee; Choi, Hyun Jin; Cho, Heeyeon; Lee, Jung Won; Shin, Jae Il; Cho, Min Hyun; Lee, Joo Hoon; Park, Young Seo; Ha, Il Soo; Cheong, Hae Il; Kim, Su Young; Lee, Seung Joo; Kang, Hee Gyung.

In: Medicine (United States), Vol. 97, No. 46, e13157, 01.11.2018.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Efficacy and safety of rituximab in childhoodonset, difficult-to-treat nephrotic syndrome

T2 - A multicenter open-label trial in Korea

AU - Ahn, Yo Han

AU - Kim, Seong Heon

AU - Han, Kyoung Hee

AU - Choi, Hyun Jin

AU - Cho, Heeyeon

AU - Lee, Jung Won

AU - Shin, Jae Il

AU - Cho, Min Hyun

AU - Lee, Joo Hoon

AU - Park, Young Seo

AU - Ha, Il Soo

AU - Cheong, Hae Il

AU - Kim, Su Young

AU - Lee, Seung Joo

AU - Kang, Hee Gyung

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Background: The anti-CD20 monoclonal antibody rituximab (RTX) has been proposed as a rescue therapy for difficult-to-treat nephrotic syndrome (NS). We conducted a clinical trial to evaluate the efficacy and safety of RTX in children with difficult-to-treat NS dependent on or resistant to steroids and calcineurin inhibitors (CNIs). Methods: A multicenter open-label trial was performed at 8 major pediatric nephrology centers in Korea. The investigation consisted of a randomized controlled trial for steroid- and CNI-dependent NS (DDNS; randomization into the RTX group and the control group, at a ratio of 2:1) and a single-arm study of steroid and CNI-resistant NS (DRNS). DDNS patients in the RTX group and DRNS patients received a single dose of intravenous RTX (375mg/m2 of body surface area) for B-cell depletion. A second RTX dose was administered at week 2 if the first dose failed to achieve depletion of CD19(+) cells. The primary endpoint was rate of maintaining remission at 6 months after treatment for DDNS and rate of remission achievement for DRNS. Results: Sixty-one children with DDNS were enrolled while in remission and randomized to the control group (21 patients) or the RTX group (40 patients). At 6 months after treatment, the remission rates were 74.3% in the RTX group and 31.3% in the control group (P=.003). The mean duration of remission maintenance was significantly higher in the RTX group than in the control group (9.0 vs 2.9 months, P=.004). Of the 23 patients with DRNS enrolled in the single-arm study and treated with RTX, 9 (39.1%) achieved partial or complete remission within 6 months. Depletion of B cells occurred in all patients with RTX therapy. Thirty patients (50.8% of 59 patients analyzed) experienced mild and transient infusion reaction during RTX administration, and most adverse events were mild. Conclusions: RTX administration was safe and effective in patients with difficult-to-treat NS. One or 2 doses of RTX may be sufficient to deplete B cells and achieve better control of pediatric NS.

AB - Background: The anti-CD20 monoclonal antibody rituximab (RTX) has been proposed as a rescue therapy for difficult-to-treat nephrotic syndrome (NS). We conducted a clinical trial to evaluate the efficacy and safety of RTX in children with difficult-to-treat NS dependent on or resistant to steroids and calcineurin inhibitors (CNIs). Methods: A multicenter open-label trial was performed at 8 major pediatric nephrology centers in Korea. The investigation consisted of a randomized controlled trial for steroid- and CNI-dependent NS (DDNS; randomization into the RTX group and the control group, at a ratio of 2:1) and a single-arm study of steroid and CNI-resistant NS (DRNS). DDNS patients in the RTX group and DRNS patients received a single dose of intravenous RTX (375mg/m2 of body surface area) for B-cell depletion. A second RTX dose was administered at week 2 if the first dose failed to achieve depletion of CD19(+) cells. The primary endpoint was rate of maintaining remission at 6 months after treatment for DDNS and rate of remission achievement for DRNS. Results: Sixty-one children with DDNS were enrolled while in remission and randomized to the control group (21 patients) or the RTX group (40 patients). At 6 months after treatment, the remission rates were 74.3% in the RTX group and 31.3% in the control group (P=.003). The mean duration of remission maintenance was significantly higher in the RTX group than in the control group (9.0 vs 2.9 months, P=.004). Of the 23 patients with DRNS enrolled in the single-arm study and treated with RTX, 9 (39.1%) achieved partial or complete remission within 6 months. Depletion of B cells occurred in all patients with RTX therapy. Thirty patients (50.8% of 59 patients analyzed) experienced mild and transient infusion reaction during RTX administration, and most adverse events were mild. Conclusions: RTX administration was safe and effective in patients with difficult-to-treat NS. One or 2 doses of RTX may be sufficient to deplete B cells and achieve better control of pediatric NS.

UR - http://www.scopus.com/inward/record.url?scp=85056613170&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056613170&partnerID=8YFLogxK

U2 - 10.1097/MD.0000000000013157

DO - 10.1097/MD.0000000000013157

M3 - Article

C2 - 30431588

AN - SCOPUS:85056613170

VL - 97

JO - Medicine (United States)

JF - Medicine (United States)

SN - 0025-7974

IS - 46

M1 - e13157

ER -